Topics

Incyte enters $900M deal with MorphoSys for lymphoma drug tafasitamab

05:09 EST 15 Jan 2020 | SmartBrief

A $900 million deal with MorphoSys will grant Incyte rights to the former's candidate tafasitamab for diffuse large B cell ly -More

Original Article: Incyte enters $900M deal with MorphoSys for lymphoma drug tafasitamab

NEXT ARTICLE

More From BioPortfolio on "Incyte enters $900M deal with MorphoSys for lymphoma drug tafasitamab"

Quick Search